

Date: September 16, 2022 Subject: Tyme Technologies, Inc. – Contract Adjustment **Option Symbol: TYME** New Symbol: SYRS1 Date: 09/19/2022 **Contract Adjustment** Date: September 19, 2022 **Option Symbol:** TYME changes to SYRS1 Strike Divisor: 1 Contracts Multiplier: 1 New Multiplier: 100 (e.g., a premium of 1.50 yields \$150; a strike of 1 yields \$100.00) New Deliverable Per Contract: 1) A number of Syros Pharmaceuticals, Inc. (SYRS) Common Shares equal to the exchange ratio as described in the TYME/SYRS Joint Proxy Statement/Prospectus dated August 8, 2022 ("Proxy") x 100 2) Cash in lieu of fractional SYRS shares, if any Note: Once determined the cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security. CUSIP: SYRS: 87184Q206

Delayed Settlement

OCC will delay settlement of the SYRS and cash portion of the SYRS1 deliverable until the final merger consideration and cash in lieu of fractional SYS shares, if any, are determined. Upon determination of the final merger consideration and cash in lieu amount, if any, OCC will require Put exercisers and Call assignees to deliver the appropriate number of shares and cash amount.

Background

#51039

On September 15, 2022, Shareholders of Tyme Technologies, Inc. (TYME) voted concerning the proposed merger with Syros Pharmaceuticals, Inc. (SYRS). The merger was approved and subsequently consummated on September 16, 2022. As a result, each existing TYME Common Share will be converted into the right to receive a number of SYRS Common Shares based on the exchange ratio as described in the Proxy. Cash will be paid in lieu of fractional SYRS shares, if any.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.